Rockefeller Capital Management L.P. Sells 147,931 Shares of Astrazeneca Plc $AZN

Posted by Geri Gentry on Jun 20th, 2026

Rockefeller Capital Management L.P. lowered its stake in shares of Astrazeneca Plc (NYSE:AZN – Free Report) by 18.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 654,439 shares of the company’s stock after selling 147,931 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Astrazeneca were worth $114,854,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of AZN. MV Capital Management Inc. bought a new stake in Astrazeneca during the 4th quarter valued at approximately $26,000. Reflection Asset Management bought a new position in shares of Astrazeneca in the 4th quarter worth approximately $31,000. Lloyd Advisory Services LLC. purchased a new position in shares of Astrazeneca in the 4th quarter valued at approximately $35,000. Basepoint Wealth LLC purchased a new position in shares of Astrazeneca in the 4th quarter valued at approximately $44,000. Finally, Acumen Wealth Advisors LLC bought a new stake in shares of Astrazeneca during the fourth quarter valued at approximately $47,000. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Astrazeneca Stock Performance

Astrazeneca stock opened at $174.87 on Friday. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $271.20 billion, a P/E ratio of 26.26, a PEG ratio of 1.52 and a beta of 0.25. The stock’s 50 day moving average is $186.62 and its 200 day moving average is $186.27. Astrazeneca Plc has a twelve month low of $137.23 and a twelve month high of $212.71.

Astrazeneca (NYSE:AZN – Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. The business had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. On average, equities research analysts predict that Astrazeneca Plc will post 9.39 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

AZN has been the topic of several recent research reports. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Astrazeneca in a research note on Monday, June 8th. TD Cowen reissued a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. UBS Group restated a “buy” rating on shares of Astrazeneca in a report on Friday, April 10th. Morgan Stanley reaffirmed an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. Finally, Barclays reiterated a “buy” rating on shares of Astrazeneca in a research note on Monday, June 1st. Twelve investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $205.33.

Read Our Latest Research Report on AZN

Astrazeneca Profile

(Free Report)

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.